BRIEF-Oncolytics Biotech® Aligns With FDA On Pivotal Study Design For Pelareorep In First-Line Pancreatic Cancer

Reuters
Nov 19
BRIEF-<a href="https://laohu8.com/S/ONCWF">Oncolytics Biotech</a>® Aligns With FDA On Pivotal Study Design For Pelareorep In First-Line Pancreatic Cancer

Oncolytics Biotech Inc ONCY.O:

  • ONCOLYTICS BIOTECH® ALIGNS WITH FDA ON PIVOTAL STUDY DESIGN FOR PELAREOREP IN FIRST-LINE PANCREATIC CANCER

  • ONCOLYTICS BIOTECH INC - TO LAUNCH IMMUNOTHERAPY TRIAL IN PANCREATIC CANCER IN 2026

Source text: ID:nBw8FR6H3a

Further company coverage: ONCY.O

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10